Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03410654 · ClinicalTrials.gov registry record · Early Phase 1
Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 28
- Enrollment target
NCT03410654 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 28 participants.
The verdict
NCT03410654, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if cognitive function improves in patients converted from tacrolimus immediate release (TAC IR) to Envarsus XR® (tacrolimus extended release) using an objective measure of cognition.
Interventions
- DRUG Tacrolimus, Extended Release, (Envarsus Xr)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-10-24 |
| Est. Completion | 2024-07-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03410654
The ClinicalTrials.gov registry entry for NCT03410654 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tacrolimus, Extended Release, (Envarsus Xr) is the first listed.
NCT03410654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03410654 about?
NCT03410654 is a clinical study titled "Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.". The purpose of this study is to determine if cognitive function improves in patients converted from tacrolimus immediate release (TAC IR) to Envarsus XR® (tacrolimus extended release) using an objective measure of cognition.
What is the current status of trial NCT03410654?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 28 participants. The study started on 2018-10-24. Estimated completion is 2024-07-01.
What interventions are being tested in trial NCT03410654?
The interventions under investigation include: Tacrolimus, Extended Release, (Envarsus Xr) (DRUG).
Who is sponsoring clinical trial NCT03410654?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.